Taysha Gene Therapies, Inc. (TSHA) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Taysha (TSHA) Q1 2026: R&D Spend Climbs 116% as BLA Submission Nears for Rett Gene Therapy
May 06, 2026
-
Taysha (TSHA) Q4 2025: $20M R&D Surge Accelerates TASHA-102 Pivotal Pathway
March 19, 2026
-
Taysha Gene Therapies (TSHA) Q3 2025: Breakthrough Designation Secured as 100% Response Rate Achieved in High-Dose Cohort
November 04, 2025
-
Taysha (TSHA) Q2 2025: $230M Raise Extends Runway, Pivotal Rett Trial Site Activation Signals Regulatory Momentum
August 12, 2025
-
Taysha (TSHA) Q1 2025: FDA Alignment Accelerates Pivotal Trial Pathway for Rett Gene Therapy
July 07, 2025